A randomized, placebo-controlled, phase II study of obeticholic acid for primary sclerosing cholangitis
Top Cited Papers
Open Access
- 1 July 2020
- journal article
- research article
- Published by Elsevier BV in Journal of Hepatology
- Vol. 73 (1), 94-101
- https://doi.org/10.1016/j.jhep.2020.02.033
Abstract
No abstract availableKeywords
Funding Information
- Intercept Pharmaceuticals, Inc
This publication has 20 references indexed in Scilit:
- Effect of NGM282, an FGF19 analogue, in primary sclerosing cholangitis: A multicenter, randomized, double-blind, placebo-controlled phase II trialJournal of Hepatology, 2018
- Design and Endpoints for Clinical Trials in Primary Sclerosing CholangitisHepatology, 2018
- FXR activation by obeticholic acid or nonsteroidal agonists induces a human-like lipoprotein cholesterol change in mice with humanized chimeric liverJournal of Lipid Research, 2018
- Primary sclerosing cholangitis – a comprehensive reviewJournal of Hepatology, 2017
- Surrogate endpoints for clinical trials in primary sclerosing cholangitis: Review and results from an International PSC Study Group consensus processHepatology, 2015
- Efficacy of Obeticholic Acid in Patients With Primary Biliary Cirrhosis and Inadequate Response to Ursodeoxycholic AcidGastroenterology, 2015
- Association Between Reduced Levels of Alkaline Phosphatase and Survival Times of Patients With Primary Sclerosing CholangitisClinical Gastroenterology and Hepatology, 2013
- Improvement of serum alkaline phosphatase to <1.5 upper limit of normal predicts better outcome and reduced risk of cholangiocarcinoma in primary sclerosing cholangitisJournal of Hepatology, 2012
- High-dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitisHepatology, 2009
- High-Dose Ursodeoxycholic Acid in Primary Sclerosing Cholangitis: A 5-Year Multicenter, Randomized, Controlled StudyGastroenterology, 2005